TORONTO--(BUSINESS WIRE)--Enigma Biomedical Group today announced a clinical research agreement with McGill University Research Centre for Studies in Aging in Montreal to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
“We are proud to partner with McGill University Research Centre for Studies in Aging, one of the premier institutions in the world. This is another important step in our ongoing and long-term relationship with McGill.”
As part of the agreement, Enigma will provide funding for various research projects, and through its US entity Cerveau Technologies, Inc., will supply the MK-6240 precursor needed for the initiatives.
Lee Anne Gibbs, President of Enigma Biomedical Group said, “We are proud to partner with McGill University Research Centre for Studies in Aging, one of the premier institutions in the world. This is another important step in our ongoing and long-term relationship with McGill.”
Dr. Pedro Rosa-Neto, Director of McGill University Research Centre for Studies in Aging said, “These research projects will provide valuable insight into the status and progression of NFTs in healthy subjects, subjects with mild cognitive impairment and confirmed Alzheimer’s Disease. We appreciate the support of Enigma Biomedical Group and value our ongoing relationship.”
Dr. Serge Gauthier, Director of the AD & Related Disorders Research Unit of the McGill University Research Center for Studies in Aging said: “The ability to visualize and quantify tau in the brain will facilitate therapeutic research in the field of Alzheimer's disease.”
“At Cerveau, we are focused on providing information and technologies to researchers and clinicians to improve brain health,” said Rick Hiatt, President of Cerveau Technologies, Inc., and CEO of Enigma Biomedical Group. “We are excited by the opportunity to work with McGill and the pharmaceutical industry in providing access to this novel imaging agent to the broader scientific community."
About Enigma Biomedical Group
Toronto based Enigma Biomedical Group (EBG) enhances access to key technologies with a focus on molecular imaging and medicine. EBG offers a suite of services to the pharmaceutical industry and clinical research community to accelerate drug development and global access. EBG partners with academic institutions and universities to foster and broaden access to novel research. More information can be found at http://www.enigmabiomedicalgroup.com/.
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.